Global programmatic use of bedaquiline and delamanid for drug-resistant TB treatment: progress, challenges, and possible solutions Dr. Vivian Cox Chair,

Slides:



Advertisements
Similar presentations
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Advertisements

AVOID A CHRONIC PAIN AS A PATIENTS’ RIGHT Teresa Petrangolini Active Citizenship Network - PAE.
Manila, Dec.2014 NEW DRUGS INTRODUCTION IN VIETNAM – SHORT PROGRESS UPDATE.
Technical Advisory Group meeting, WHO/WPRO
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Trinidad & Tobago Corporate Governance Code 2013
Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting.
The Global Fund- structure, function and evolution February 18, 2008.
AMFm Overview and Case Management Observations RBM Case Management Working Group (CMWG)
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Program Co-Development in CME: Where have we been? Where are we going? Workshop Facilitators: Dr. Craig Campbell Dr. Jamie Meuser September 21,
PRESENTATION: PORTFOLIO COMMITTEES ON CORRECTIONAL SERVICES AND HEALTH PROVISION OF HEALTH CARE WITHIN CORRECTIONAL CENTRES 1.
October 31, 2014 Satellite Symposium: The pediatric TB drug market: progress and future direction Market understanding: new data on the purchasing habits.
Collaborative TB/HIV activities Update on Progress Diane V. Havlir 13 th TB/HIV Core Group meeting April 17-18, 2008 New York, USA.
Financial Disclosures Financial interests, arrangements or affiliations that could be perceived as a real or apparent “conflict of interest” in the context.
Supply Chain Management of Second Line Drugs: Russian Example Dr Vadim V. Testov Central TB Research Institute, Moscow, the Russian Federation.
Stop TB in China Challenges, Constraints & Actions Dr Wang Longde Vice Minister of Health China 24 March 2004.
MONITORING, EVALUATION & REPORTING UPDATES 2014 Annual Partners Forum 15 April 2014.
Improving Access for Quality-Assured TB Medicines and Diagnostics Medicines and Diagnostics Improving Access for Quality-Assured TB Medicines and Diagnostics.
PrEP Scale Up in Kenya: Bridge to Scale Project
STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL
Community Representative Update
In My Practice: Asthma in Portugal
TB- HIV Collaborative activities in Romania- may 2006 status
Disclosure In relation to this presentation, I declare the following, real or perceived conflicts of interest: - A conflict of interest is any situation.
The Patient Triage Concept: Right Diagnosis, Right Treatment
BFHI Congress 2016 New Guidance on the Protection, Promotion, and Support of Breastfeeding in Maternity Facilities Laurence M. Grummer-Strawn, PhD WHO.
Zimbabwe’s shift towards treat all: national country context
Neurological Clinicopathologic Case Presentation
11 ii. Develop a plan for aDSM
Global Drug Facility An innovative approach to supplying anti-TB drugs
1. Structure and training objectives for this course & key references
Contemporary Paradigms for Anticoagulant Reversal
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
HEALTH IN POLICIES TRAINING
Managing symptomatic asthma in primary care: The personalised approach
Global Youth Tobacco Survey (GYTS): Proposal Development
Novel approaches to TB infection control in private general hospitals in Georgia T Gabunia1, I Khonelidze, N Solomonia, T Merabishvili, M Makharadze,
Conflict of interest disclosure
Access Equity in Prisons in Africa A CALL FOR ACTION
The results are in: now what?
Chair, DR-TB STAT Task Force
Speaker Disclosure slides for presentations
Conflict of Interest Disclosure Form
Introducing new drugs and shorter regimen
World Health Organization
Update on SBCC Activities of Challenge TB Bangladesh
Conflict of Interest Disclosure
Accelerating Cervical Cancer Elimination
FINANCIAL DISCLOSURES
Finance & Planning Committee of the San Francisco Health Commission
Conflict of interest disclosure
Financial Disclosure Financial Interest / Affiliation
Disclosures Relevant financial relationships in the past twelve months by presenter or spouse/partner.    Employment: Company Name(s) Speakers Bureau:
Issues Workshop Year of Action for Ending Tuberculosis
Title of Talk Speaker name.
Conflict of Interest Disclosure Form
MDR-TB Clinical Trials Landscape Overview: Current and Future Trials
Clinical trial capacity building to address MDR-TB: challenges and the way forward
List disclosure information here.
Financial and Other Disclosures
Conflict of Interest Disclosure Form DISCLOSURE
Name of Activity / Session
Abstract Problem Statement: Armenia received anti-TB drugs from the Global Drug Facility to treat patients in the civil sector in January 2003, whereas.
Update on global progress in ART
Conflict of Interest Disclosure Form
How are programmes specifically designed using collected data?
Presentation transcript:

Global programmatic use of bedaquiline and delamanid for drug-resistant TB treatment: progress, challenges, and possible solutions Dr. Vivian Cox Chair, DR-TB Scale-Up Treatment Action Team (DR-TB STAT) Task Force USAID/STBP MDR-TB Clinical Consultant

Conflict of interest disclosure This event is accredited for CME credits by EBAP and speakers are required to disclose their potential conflict of interest going back 3 years prior to this presentation. The intent of this disclosure is not to prevent a speaker with a conflict of interest (any significant financial relationship a speaker has with manufacturers or providers of any commercial products or services relevant to the talk) from making a presentation, but rather to provide listeners with information on which they can make their own judgment. It remains for audience members to determine whether the speaker’s interests or relationships may influence the presentation. Drug or device advertisement is strictly forbidden. Conflict of interest disclosure X I have no, real or perceived, direct or indirect conflicts of interest that relate to this presentation. I have the following, real or perceived direct or indirect conflicts of interest that relate to this presentation: Affiliation / financial interest Nature of conflict / commercial company name Tobacco-industry and tobacco corporate affiliate related conflict of interest Grants/research support (to myself, my institution or department): Honoraria or consultation fees: Participation in a company sponsored bureau: Stock shareholder: Spouse/partner – conflict of interest (as above): Other support or other potential conflict of interest:

Outline Global progress on introduction of newer drugs Uptake of BDQ and DLM in the PAHO region Barriers to newer drug access Potential solutions

Timeline: introduction of bedaquiline and delamanid December 2012 FDA grants accelerated approval for bedaquiline June 2013 WHO releases interim guidelines for use of bedaquiline to treat DR-TB March 2014 EMA conditionally approves bedaquiline April 2014 EMA conditionally approves delamanid October 2014 WHO releases interim guidelines for use of delamanid to treat DR-TB May 2015 WHO adds bedaquiline and delamanid to Essential Medicines List April 2015 Janssen/USAID launch bedaquiline donation program Otsuka announces FighTBack Initiative delamanid donation program October 2015 Georgia becomes first country to receive donated bedaquiline October 2016 WHO guideline update on the use of shorter MDR-TB regimen WHO releases guidance on delamanid use for DR-TB in children March 2017 WHO releases GDG meeting report on the use of bedaquiline for DR-TB September 2017 WHO releases statement on off-label use of bedaquiline and delamanid December 2017 Five years after bedaquiline approval

Progress of global BDQ introduction 10,164 patients have received BDQ as of 1 July 2017 13,825 orders from the Global Drug Facility Registered in 18 countries; under assessment in 16 (11/30 high DR-TB burden countries without submission) 80% of BDQ access in South Africa and Russia 3,441

Global BDQ implementation *As of 1 July 2017

Progress of global DLM introduction 688 patients have received DLM as of 1 July 2017 3,238 orders from the Global Drug Facility Registered in 6 countries; under assessment in 4 (25/30 high DR-TB burden countries without submission) 79% of DLM access through Unitaid endTB project *adjusted to exclude compassionate use of DLM in November 2016

Global DLM implementation *As of 1 July 2017

Global Progress: BDQ and DLM *adjusted to exclude compassionate use of DLM in November 2016

Global progress: BDQ and DLM versus minimum estimated global need *calculation of global estimated need for newer drugs adjusted to reflect cumulative number of patients started on treatment for RR-TB in 2015 and 2016

14% (OOS 5%)

Uptake of BDQ and DLM: PAHO region Brazil is a high-burden TB country and Peru is a high-burden MDR-TB country Overall it is estimated that there are more than 7,000 persons in the PAHO region who needed newer drugs over the two year period between 2015 and 2017 Fewer than 150 people in the PAHO region have received newer drugs under program conditions, just over 2% of those who needed them PAHO countries that have introduced newer drugs under program conditions: Peru, Haiti and the Dominican Republic Brazil: compassionate use access for newer drugs Delamanid orders via GDF only for Dominican Republic (4 treatments) Bedaquiline orders via GDF for Dominican Republic (34 treatments), Peru (211 treatments), Haiti (20 treatments), Bolivia (3 treatments)

Reported barriers to newer drug introduction (1) Guidelines Interpretation of WHO guidelines in country context Guideline revision process, including training Concerns about off label use and use in special populations, especially with donation program drugs Establishing PV / aDSM Wanting to collect own efficacy data Adding newer drugs to a long, toxic regimen Cost, registration, importation Health system strengthening

Reported barriers to newer drug introduction (2) Guidelines Cost, registration, importation BDQ: donation program or tiered pricing; DLM: GDF pricing Registration (BDQ: 18 countries; DLM: 6 countries) Health system strengthening Weaknesses in current DR-TB programme Restriction of newer drug use to few centralized facilities Requirement to hospitalize cases to initiate newer drugs Lack of monitoring equipment Lack of SL LPA and/or phenotypic DST Weak community support systems for DR-TB patients Poor support from Ministry of Health

Contrast in access to BDQ and DLM Timeline of WHO recommendations doesn’t fully explain differential use Potential reasons for gap in access: Cost – purchase from GDF started in Feb 2016, only if GF-eligible Registration – proactivity of Janssen (e.g. CRP) Early access programmes – built clinical experience in country Country level decisions – sequential systems for BDQ then DLM BD dosing – impact on DOTS programmes and resources

Global access to newer drugs: potential solutions WHO guideline recommendations update Expand/re-organize technical assistance to countries to absorb current and future innovations Streamline pre-qualification and registration processes for new drugs Engage and educate communities on newer drugs Set targets Country targets Regional targets Access, registration, time to patient targets Set targets before access is needed Engage with civil society to create accountability

Acknowledgements